bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSun Yat-sen University
About this trial
This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (bTAE-HAIC) plus Lenvatinib and Camrelizumab for patients with infiltrative hepatocellular carcinoma.
Eligibility criteria
Qualifiers
Diagnosis of infiltrative HCC.
Infiltrative HCC was characterized as follows: nonencapsulated arterial phase hyperenhancement; tumor washout in the period of portal phase, and noncircular, ill-defined margin
Age between 18 and 75 years;
The maximum tumor size ≥10 cm, and the total tumor size ≥15 cm;
Disqualifiers
HCC with capsule;
Extrahepatic metastasis >5;
Obstructive PVTT involving the main portal vein.
Serious medical comorbidities.
Trial design
Treatments tested in this trial
- bTAE-HAIC
- Lenvatinib
- Sintilimab
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov